BioAge, IPO
Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO
Obesity drug developer BioAge Labs (BIOA) has filed regulatory filings as part of its U.S. IPO. It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at the midpoint. Sofinnova Venture Partners, a leading BioAge ...
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a private placement.
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering. The company was founded in 2015 and plans to list on the Nasdaq under the symbol BIOA.
Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.
Drugmaker seeks $157.5M in IPO, placement
BioAge Labs, a clinical-stage biotech firm focused on obesity and metabolic disease therapies, aims to raise up to $157.5 million through its initial public offering and private placement, Bloomberg reported Sept. 18.
Obesity drugmaker BioAge targets $158 million in IPO
The company is offering 7.5 million shares for $17 to $19 apiece, according to a filing Wednesday
Health News | Today's Latest Stories | Reuters
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
Diabetes.co.uk15d
New weight loss drug targets the elderly
Partnering with pharmaceutical giant Eli Lilly, BioAge is looking to create a new weight management solutions for older ...
Opinion
Aging is the inflation of life. An emerging crop of longevity biotech companies needs investment to beat it
A new generation of longevity biotech companies with a more conservative approach than their predecessors has emerged—but investment remains constrained.
Initial public offerings scheduled to debut next week
NEW YORK (AP) — The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings.
pharmaphorum2d
Respiratory biotech Upstream joins Nasdaq IPO surge
It is joining the initial public offering (IPO) queue amid a flurry of IPO activity in the sector, with three biotechs ...
BioSpace16d
Lilly Partner BioAge Files for IPO to Advance Obesity Candidate
BioAge will use the proceeds from the initial public offering to move its oral apelin receptor agonist azelaprag past its ...